In addition, we propose a novel PPARα agonist, DhT, to treat NAFLD, through a mechanism by which DhT activates and binds to PPARα agonist to down‐regulate FC‐induced ROS burst, therefore showing protective efficacy. Here, PPARA is linked to metabolic dysfunction-associated steatotic liver disease.